Cargando…
Safety profile of the lopinavir/ritonavir combination before and during the SARS-CoV-2 pandemic
INTRODUCTION: When the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic began, there were no effective treatments assessed by clinical trials. In this context, in France, the French Public Health Council issued, from 5 March, 2020, several proposed recommendations for the therap...
Autores principales: | Lory, Pauline, Combret, Sandrine, Michot, Joelle, Veyrac, Gwenaelle, Chouchana, Laurent, Grandvuillemin, Aurélie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618454/ https://www.ncbi.nlm.nih.gov/pubmed/36376122 http://dx.doi.org/10.1016/j.therap.2022.10.066 |
Ejemplares similares
-
Comparative study of the adverse event profile of hydroxychloroquine before and during the Sars-CoV2 pandemic
por: Lory, Pauline, et al.
Publicado: (2022) -
Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre
por: Istampoulouoglou, Ioanna, et al.
Publicado: (2021) -
Monitoring the safety of drugs and COVID-19 vaccines by the French Pharmacovigilance Centers during the pandemic: A win-win bet with Health Authorities!
por: Jonville-Bera, Annie Pierre, et al.
Publicado: (2023) -
French pharmacovigilance survey of casirivimab - imdevimab monoclonal antibodies in coronavirus disease (COVID-19)
por: de Canecaude, Claire, et al.
Publicado: (2023) -
Pharmacovigilance des médicaments et des vaccins contre la COVID-19 durant la pandémie : comment le Réseau français des centres régionaux de pharmacovigilance a relevé le défi ?
por: Jonville-Bera, Annie Pierre, et al.
Publicado: (2023)